Immuron Announced Travelan Sales Continued Strong Growth

Author: Charles Gross | April 09, 2024 09:01pm

Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract,

Sales Highlights: Global • FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcp • Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia • FYTD Mar 2024 AUD$2.8 million up 234% on pcp • Mar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% on last quarter USA • FYTD Mar 2024 AUD$0.8 million up 35% on pcp • Mar 2024 Quarter AUD$0.3 million up 7% on pcp and 18% on last quarter • Sales commenced on Walmart.com  

Posted In: IMRN WMT